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Abstract Formoterol fumarateis a b2-agonistbronchodilator thatcombines a fastonsetof actionwith a longduration
of action.Its fastonsetof actioniswelldocumentedin asthmabuthasnotbeendirectlycomparedwiththatof salbutamol
in patients with chronic obstructive pulmonary disease (COPD). This randomized, double-blind, placebo-controlled
studywas conductedto assess thebronchodilatorye¡ects over the ¢rst 3 h afterinhalationof single dosesof formoterol
24 mgdeliveredviatheAerolizerTMdrypowderinhalerdevice(double-blind),orsalbutamol400 mgdeliveredviaDiskhaler1
drypowder inhaler (single-blind) in patientswith COPD.Atotal of 24 patientswith COPDwere randomized [mean age
61?6+7?8 years, mean forced expiratory volumein1sec (FEV1) 1?38+0?32 l and 45?8+9?6% ofpredicted].Inhalationof
formoterol or salbutamol resulted in similar increases in FEV1 from 0 to 3 h post-dose. Both drugs produced similar
bronchodilation by 5min, which became almostmaximal by 30min.The primary e⁄cacy variable, the area under the
curve (AUC) of the FEV1 increase above predose baseline from 0 to 30min (AUC0730min), demonstrated signi¢cant
e¡ects for formoterol (mean 5?89+4?67 lmin71), and salbutamol (mean 6?06+4?34 lmin71), whichwere not statisti-
cally di¡erent from each other but statistically signi¢cantly higher (P50?0001) than that observed with placebo
(70?32+2?59 lmin71). In addition, both formoterol and salbutamolproduced similar and rapid increases in forced vital
capacity (FVC). In summary, this study con¢rms the rapid onset of action of formoterol and indicates that the onset of
action of formoterol and salbutamol are similar inpatientswith COPD.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1161, available online at http://www.idealibrary.comon
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Formoterol (Foradil1) is a unique b2-agonist that com-
bines the clinical bene¢ts of a long duration of action
with a rapid onset of action (1). In a placebo-controlled
trial with formoterol delivered via the AerolizerTM dry
powder inhaler, Maesen et al. (2) were able to show that
patients’ subjective perception of the onset of broncho-
dilation matched objective clinical measurement of the
onsetof bronchodilation. In addition, in comparative clin-
ical trials in patientswithmoderately severe asthma, for-
moterol has been shown to have a similar onset of action
to salbutamol producing signi¢cant bronchodilation
within1min after inhalation (3^5).Not only is fast onset
of action important for patient re-assurance of promptReceived1June 2001and accepted in revised form15 June 2001
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compliance; if symptom relief is experienced rapidly
after dosing, the patient feels that the treatment is e¡ec-
tive andwill continuewith it.
Chronic obstructive lung disease (COPD) di¡ers from
asthma in that it is a chronic progressive condition that
requires regular long-term treatment once the individual
has progressed beyond the initial stages of the disease
(6).This treatment is maintained at the same level or in-
creased as needed; there is no step-down therapy.
Bronchodilators are central to the symptomatic treat-
ment of COPD and whilst the short acting b2-agonists
are regularly prescribed the bene¢ts they o¡er in COPD
when used frequently in COPD are not clear.The bene-
¢ts of longer-acting bronchodilators over regular use of
short-acting bronchodilators is becoming more clear
with the publication of new data that suggest that early
intervention with formoterol may be a useful strategy
for some patients with COPD (7,8). Clinical trials in
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odilator in patients who have di¡ering degrees of forced
expiratory volume in 1sec (FEV1) reversibility (both
15% and515% of the baseline value) (9,10). It provides
signi¢cantly greater bronchodilation than ipratropium
(7), with a sustained improvement in lung function that
is superior to theophylline (8,11). The onset of action of
formoterol in COPD has been shown to be faster than
that of ipratropium (12) but has not been directly com-
paredwith that of salbutamol.
Thepurpose of this current study was to compare the
onset of action of formoterol in COPD with salbutamol,
in order to de¢ne further the potential role of
formoterol in COPD. The primary objective was to
assess the bronchodilatory e¡ects of formoterol and
salbutamol compared with placebo in terms of the FEV1
area under the curve from 0 to 30min (AUC0730min)
following single-dose administration. Secondary
objectives were to compare the bronchodilatory e¡ects
of these two drugs with placebo with respect to other
e⁄cacy variables during 3 h following a single dose.
METHODS
Study design
The study was designed as a randomized, placebo-
controlled, double-blind for formoterol and placebo,
single-blind for salbutamol, three-way, cross-over trial.
Salbutamol reversibility testing was performed during a
7-day screening phase, which was followed by randomi-
zation at the start of themain trial.The three-waycross-
over design allowed intermittent comparisons and a
double-blind (for formoterol and placebo); single-blind
(for salbutamol) design was used to minimize bias.
Double-blind treatment with salbutamol was not
possible owing to the unavailability of placebo matched
to salbutamol.
Study population
A total of 40 patientswere screened and 25were rando-
mized. All patients were between the ages of 40^75
years with stable COPD according to inclusion criteria.
Patients were selected on the basis of a history of smok-
ing of420 pack-years, who met the following criteria:
(a) a diagnosis of COPDbased on theAmerican Thoracic
Society guidelines (13); (b) FEV1of between 30% and 60%
of the predicted value and at least1000 ml after at least
6 h wash-out from short-acting bronchodilators, with
FEV1/FVC 588% of predicted in men or 89% of pre-
dicted inwomen; (c) demonstrable intermediate reversi-
bility with an increase in FEV1of 200mlmaximumand 5^
15% over baseline within 30 min of 400mg salbutamol
(26200mg VentodiskTM). Exclusion criteria included all
patients with a signi¢cant medical condition and those
who had been hospitalized for an acute exacerbation ofCOPD within 1 month prior to the start of the study.
Patients using non-potassium-sparing diuretics, b-block-
ing agents, quinidine or quinidine-like medications
(anti-arrhythmics), tricyclic anti-depressants, selective
serotonin re-uptake inhibitors and monoamine oxidase
inhibitors were also excluded from the trial.
Use of oral corticosteroids, theophylline or other
xanthine derivatives, oral or inhaled anti-cholinergics,
oral or inhaled long-acting b2-agonists, or inhaled short-
acting b2-agonists were not allowed during the main
study period.
Treatments
Treatments consisted of a single dose of each trial medi-
cation administered as follows: formoterol 24mg, given
as two dry powder capsules each containing12mg of for-
moterol via AerolizerTM (Novartis Pharma AG, Basel,
Switzerland); placebo, matched to formoterol dry pow-
der capsules via AerolizerTM (Novartis Pharma AG); sal-
butamol 400mg, two pu¡s of dry powder (VentodiskTM
200mg) via DiskhalerTM, 200mg per pu¡ (Glaxo Well-
come, France).
Treatment with inhaled or nasal corticosteroids and
rescue medication with salbutamol between visits was
allowed during the trial.
E⁄cacy assessments
The primary e⁄cacy parameter was AUC0730min of
FEV1 in lmin
71. Secondary e⁄cacy parameters included:
AUC071h of FEV1 (lmin
71), AUC073h of FEV1 (lmin
71),
maximal change in FEV1 as a percentage of predicted
value, maximal change in FEV1 in litres, and maximal
change frompredose in forcedvital capacity (FVC) in litres.
Other spirometric measurements included FEV1 and
FVC, measured during screening (qualifying value for
reversibility), and before dosing and 5,10, 15 and 30min,
1h, 2h, 3 h and 4h after dosing at during the main trial.
Spirometry had to be performed within +1min of the
scheduled 5-min time point and within +5min of the
scheduled 15-min, 30-min, 1-h, 2-h, 3-h and 4-h time
points.
Safety assessments
All adverse events were recorded and vital signs includ-
ing pulse rate and blood pressure were measured after
5 min rest at each visit.
Statisticalmethods
The primary e⁄cacy variable was the AUC0730min of
FEV1 (lmin
71), calculated from repeated measurements
of FEV1, predose and 5min, 10min, 15min, 30min after
study drug intake at each visit. Absolute level of FEV1 (l)
TABLE 1. Baseline demographics and background char-
acteristics.ITT population





Duration of COPD (years) 11?9+7?8
Smokinghistory (pack-years) 48?0+17?36
Current smokers 11 (45?8%)
Previous smokers 13 (54?2%)
Lung function
Baseline FEV1 (l) 1?38+0?32
FEV1/FVC (%) 54?3+8?3




FIG. 1. FEV1AUCvalues for the ¢rst 3 h following inhalation of
formoterol 24 mg (&), salbutamol 400 mg (&) or placebo (&).
ITT population (n24).Values are shown as mean+SD for the
ITT population. ***P50?0001vs. placebo.
RAPIDBRONCHODILATIONWITHFORMOTEROLINCOPD 819wasusedin this calculation.Ananalysis of variancemodel
including sequence, treatment, visit and patient (ran-
dom) as factors was used for analysis.
Pairwise comparisons between treatment means
were based on t-tests using the pooled error term of
the model. The main comparison of interest being that
of formoterol with placebo, no adjustment for multiple
comparisons wasmade.
AUC071h (lmin
71) and AUC073h (lmin
71), maximal
change in FEV1 (expressed in litres, in percentage of
baseline value and as a percentage of the predicted
value), and maximal change in FVC (l), were analysed in
the same way as the primary e⁄cacy variable. All ana-
lyses were carried out on the ‘intent-to-treat’ (ITT)
population.
RESULTS
Baseline demographics and background
characteristics
A total of 40 patients were screened, of whom 25 were
randomized. Of the 15 patients discontinued prior to
randomization, 14 failed to ful¢l selection criteria and
one withdrew consent. One patient was included twice
in the study because of incomplete e⁄cacy data due to
a spirometer breakdown during the last assessmentö
he received the same treatment sequence twice. The
ITT population consisted of 24 patients (83?3% males
and 16?7% females). Background characteristics and
baseline spirometry are presented inTable1.
E⁄cacy results
Formoterol and salbutamol produced statistically similar
(P0?85) increases in FEV1 AUC0730min from baseline:
formoterol 5?89+4?67 lmin71, salbutamol 6?06+
4?34 lmin71.Bothbronchodilators produced statistically
signi¢cantly (P50?0001) higher FEV1 AUC0730min than
thatobservedwithplacebo(70?32+2?59 lmin71)(Fig.1).
The summary statistics for the secondary e⁄cacy re-
sults are presented inTable 2.The increases in FEV1, ex-
pressed as absolute values or changes from predose or
percentage changes from predose, were very similar
from 5min to 3h after the administration of formoterol
24mg and that of salbutamol 400mg (FEV1measurements
over 3h post-dose are shown in Fig. 2).
Bronchodilation became almost maximal by 30min
with both drugs, with the majority of bene¢t (80?0% of
maximal e¡ect with both drugs) being seen at 5min.
Safety
Two patients (8%) reported adverse events which
were considered to be unrelated to the study drugs(one patient reported mild vertigo and another, acute
bronchitis). No serious adverse events were reported
and there were no discontinuations due to adverse
events. No clinically relevant changes in vital signs were
observed.
DISCUSSION
This study compared the onset of action of formoterol
delivered via the AerolizerTM dry powder inhaler, with
TABLE 2. Resultsof secondarye⁄cacyparameters following single-doseinhalationof formoterol 24 mg, salbutamol 400 mgor
placebo
Parameter Formoterol Salbutamol Placebo Formoterol vs.
salbutamol contrast
AUC071h (lmin
71) 13?08+8?79* 13?34+9?38* 0?12+5?09 P0?88
AUC073 h (lmin
71) 41?79+27?36* 41?82+27?88* 0?53+16?88 P0?99
Maximal change frompredose FEV1 (l) 0?34+0?16* 0?35+0?18* 0?11+0?08 P0?65
Maximal % change frompredose FEV1 26?0+13?3* 27?0+12?6* 8?0+6?7 P0?71
Maximal change frompredose % predicted
FEV1 (l)
11?0+5?3* 12?0+5?2* 4?0+2?7 P0?78
Maximal change frompredose FVC (l) 0?60+0?33* 0?60+0?41* 0?22+0?22 P0?96
Allresults are expressed asmean+SD.
*Statistically signi¢cantlydi¡erent fromplacebo (P50?0001).
FIG. 2. Bronchodilatore¡ectfollowingsingleinhalationofformoterol 24 mg (&), salbutamol 400 mg (~) orplacebo (*):mean FEV1
ateachtime-point inthe ¢rst 3 h post-dose.ITT population (n24).
820 RESPIRATORYMEDICINEthat of salbutamol delivered via Diskhaler1 dry powder
inhaler, in patients with COPD.
The results con¢rmed the rapid onset of action of
formoterol in COPD and showed that a single dose of
formoterol 24mg had a similar onset of action to
salbutamol 400mg observed within 5min after adminis-
tration.The increases in FEV1, with both formoterol and
salbutamol, showed little change from 5min to 3h after
administration. The mean maximal changes observed
with formoterol and salbutamolwere very similar.
This single dose comparison provides results in
patients with COPD that are similar to those obtained
in asthmatics, where the bronchodilatory e¡ects of for-
moterol are rapid and comparablewith those of salbuta-
mol (3). It also con¢rms the results of Dahletal. (12), who
showed formoterol to have an onset of action of less
than 5min in COPD, faster than that of ipratropium.Rapid onset of action is an important feature for
bronchodilators in patients with COPD, since prompt
symptom relief will give reassurance of e¡ect and could
be a key factor in patient compliance.
Patients selected for this study showed intermediate
reversibility with salbutamol (5^15% over baseline) in
order to exclude asthma categorically and to select
patients open to improvement with b2-agonist drugs.
Therefore these patients may be representative of a
potential population for reversibility testing with formo-
terol. Saligen derivatives, such as salbutamol, are only
partial agonists; in contrast, formoterol is highly potent
and displays much higher intrinsic activity, resulting in
480% relaxation even under induced tone (1).The rapid
onsetof action of formoterol and salbutamol is explained
by the ability of these drugs to reach the b2-adrenocep-
tor from the aqueous phase, but, unlike salbutamol,
RAPIDBRONCHODILATIONWITHFORMOTEROLINCOPD 821formoterol is moderately lipophilic and consequently is
retainedin themembrane lipidbilayers and thencontinu-
ously released, accounting for its long duration of action
(1,14).
The results from this study indicate that formoterol
may be considered for use in reversibility test in some
patients with COPD where its rapid onset of action is
similar to that of salbutamol but its ability to reverse air-
wayobstructionmaybe greater andmorepredictable of
the e⁄cacy of a continuous treatmentwith formoterol.
CONCLUSIONS
This study showed that formoterol and salbutamol had
similar rapid onset of bronchodilatory action in a group
of 24 patients with COPD. Both drugs produced similar
bronchodilation by 5min, which was little di¡erent to
themaximal bronchodilation. Formoterol is a unique b2-
agonistwith a rapid onsetof action and a longduration of
action (1). These two features will ensure that the
patients treated with formoterol experience rapid relief
of symptoms together with long-term control of symp-
toms, thusmaking formoterol a very useful bronchodila-
tor across the range of obstructive airways diseases.
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